The Wallace Firm Names Thomas Burns as First Partner in Firm's 9+ Year History
Accomplished trial lawyer, Thomas Burns, recognized for exceptional track record and strategic litigation expertise.
LOS ANGELES, CALIFORNIA / ACCESS Newswire / March 10, 2025 / The Wallace Firm proudly announces Thomas Burns as its first named Partner in the firm's 9+ year history, marking a major milestone in its growth and continued success.
Since joining The Wallace Firm in 2020, Burns has built an impressive track record of plaintiff results, securing numerous six- and seven-figure verdicts and settlements, with total case results reaching the mid-to-high eight figures. With nearly a decade of experience as a serious injury trial lawyer -on both the defense and plaintiff sides-Tom brings a unique strategic advantage to the firm's high-stakes litigation.
Recognized by Super Lawyers Magazine as a "Southern California Rising Star" for the fourth consecutive year (2022-2025), Burns has achieved significant outcomes in serious injury and wrongful death cases by successfully opposing summary judgment motions, tirelessly obtaining critical evidence, and thriving in jury trials.
This is a defining moment for our firm," said Bradley Wallace, Founder of The Wallace Firm. "Tom's leadership, legal expertise, and unwavering commitment to justice have helped shape our success. His promotion to Partner is a testament to the incredible work he's done and the bright future ahead for The Wallace Firm.
Burns' promotion reinforces The Wallace Firm's mission to deliver exceptional results for clients while continuing to grow as a leader in serious injury and wrongful death litigation.
Founded in 2016 by Bradley Wallace, The Wallace Firm is a premier personal injury and wrongful death law firm headquartered in Los Angeles, California. Dedicated to providing relentless advocacy and achieving outstanding results, the firm has built a reputation for excellence through compassionate client service and a commitment to justice. Specializing in serious injury, wrongful death, and complex litigation, The Wallace Firm continues to expand its impact, driven by a team of skilled attorneys passionate about making a difference. For more information, visit https://www.wallacewins.com.
Contact Information
Angel Martinez angel@wallacefirm.email+1 (818) 476-5998
SOURCE: The Wallace Firm, PC
press release
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
9 hours ago
- Associated Press
Energize Builders Expands Services With Custom Deck Construction Across Los Angeles
Los Angeles, CA - June 25, 2025 - Energize Builders, a respected Los Angeles-based construction and remodeling company, is proud to announce the launch of its dedicated deck construction services for homeowners across Southern California. Known for more than a decade of excellence in residential remodeling and new construction, the company now offers professionally designed and built custom decks to enhance outdoor living spaces. This new service reflects Energize Builders' commitment to full-spectrum home improvement, bringing the same level of craftsmanship, planning, and client collaboration to exterior projects as they do to interior remodels and full home builds. Meeting Demand for Outdoor Living Solutions As more homeowners in Los Angeles look to maximize their usable space, custom deck construction has become one of the most requested services. Whether for entertaining, dining, or quiet relaxation, a well-built deck adds both function and value to a property, especially in the year-round mild climate of Southern California. Energize Builders designs each deck to suit the home's existing style and the layout of the outdoor space. Every project is tailored, not just in size and shape, but in the features clients care about most. Options include: 'Outdoor living has become just as important as what's inside the home,' said Alik Konovalenko, owner of Energize Builders. 'We've seen growing demand from homeowners who want to create spaces that are both practical and enjoyable. Our deck construction service is a natural extension of what we already do—designing and building spaces that improve how people live.' Tailored Design and Expert Construction Energize Builders approaches every deck project with a detailed, on-site consultation to understand the client's goals, the property layout, and any unique site conditions. This allows the team to recommend the right materials, design, and structural approach from the start. Once the vision is clear, the company manages all stages of the project—from design and permitting to final construction—while keeping homeowners informed throughout the process. The team works within city and county building requirements and ensures every structure meets safety standards. A Trusted Name in Los Angeles Home Construction With over ten years of experience in custom home remodeling, new construction, and designer-led renovations, Energize Builders brings a consistent level of quality to every job, interior or exterior. The addition of deck construction builds on this foundation, offering homeowners another reliable service under one trusted roof. The company continues to serve neighborhoods across Los Angeles, including Malibu, Palisades, and Studio City, with a team that understands the unique requirements of hillside properties, urban lots, and coastal homes. 'It's not just about adding a deck—it is about creating outdoor environments that feel like a natural extension of the home,' added Konovalenko. 'We handle the details so clients can enjoy the results.' About Energize Builders Founded by Alik Konovalenko, Energize Builders is a family-owned construction company serving the greater Los Angeles area. The company specializes in: Energize Builders is known for its hands-on service, attention to detail, and long-standing relationships with both clients and design professionals. From kitchens and bathrooms to full-home renovations and now outdoor decks, the team delivers quality work that reflects each homeowner's lifestyle and vision. To learn more about deck construction in Los Angeles or to request a consultation, visit: Media Contact Company Name: Energize Builders Inc Contact Person: Alik Konovalenko Email: Send Email Phone: +1 310-963-1567 Address:13910 Fiji Way Ste 270, Marina del Rey City: Los Angeles State: CA 90292 Country: United States Website: Press Release Distributed by To view the original version on ABNewswire visit: Energize Builders Expands Services With Custom Deck Construction Across Los Angeles
Yahoo
12 hours ago
- Yahoo
Man arrested after officer pursuing suspect 'ambushed' at Santa Monica mall
June 25 (UPI) -- Police in Santa Monica, Calif., captured a suspect wanted in shooting two teens in a vehicle on Sunday and an officer injured while pursuing him at an outdoor shopping mall in Southern California on Wednesday. Police said the unnamed man was arrested about three hours after the incident at the shopping mall. UPDATE: SUSPECT IN CUSTODY The suspect involved in today's shooting of an SMPD officer has been arrested. He has also been confirmed as the individual wanted in connection with the recent Waymo vehicle shooting. We're grateful for the support of our regional partners and the... Santa Monica Police (@SantaMonicaPD) June 26, 2025 The officer recognized the alleged shooter from a wanted bulletin for a shooting incident involving a Waymo autonomous vehicle, police said. "After identifying himself as a police officer, a short foot pursuit ensued, where the officer was ambushed," Santa Monica Police Chief Ramon Batista said at a news briefing about the incident that occurred at 1:10 p.m. PDT. "The suspect fired multiple rounds at the officer and fled the area on foot." Fellow officers "quickly rendered aid" and he was taken to a local hospital with serious but non-life-threatening injuries. Police released photos of the suspect in his 30s, who was last seen wearing a dark-colored jacket and black pants. They asked anyone who recognizes or sees him to call 911. ✅ Santa Monica Place has been cleared. The suspect remains at large. See photo below. Description: Male, Black, Approximate age: 30s Wearing a dark-colored jacket and black pants If you recognize this individual or see someone matching this description, do not... Santa Monica Police (@SantaMonicaPD) June 25, 2025 They received a tip from someone who reported seeing a person matching the suspect's description. After a short foot pursuit, the suspect was arrested at 4:20 p.m. at Palisades Park about 6 miles from the mall, the chief said. Officers recovered the handgun near the suspect, according to Batista. The police chief said he has been linked to both incidents. "We are almost 100% accurate in believing that it's the same individual," Batista said. The teens suffered non-life-threatening injuries in the shooting, which occurred after an argument, police said. The suspect was considered armed and dangerous. "We are fortunate that within a short amount of time, we were able to apprehend the individual and he is no longer on the street," Santa Monica Mayor Lana Negrete said at the briefing. The 3rd Street Promenade, which is near the pier, was cleared around 3 p.m. The mall is 16 miles east of downtown Los Angeles. The public was being asked to avoid the area during the ongoing investigation. The shopping, dining and entertainment complex, which is three blocks in the downtown area, opened in 1965. It includes the upscale Santa Monica Place, which is home to more than 80 retailers, according to the city's visitation website.
Business Wire
19 hours ago
- Business Wire
Glaukos Announces EU MDR Certification for iStent infinite ® and Other Leading MIGS Therapies
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced it has received European Union (EU) Medical Device Regulation (MDR) certification for iStent infinite ®, along with several of its other leading micro-invasive glaucoma surgery (MIGS) technologies, including iStent inject ® W. Glaukos' iStent ® trabecular micro-bypass stenting platform primarily involves the insertion of a micro-scale surgical devices designed to reduce intraocular pressure by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma. "We are pleased to receive these important regulatory clearances for our leading trabecular micro-bypass stenting devices, marking our company's first approvals under the new EU regulatory framework,' said Thomas Burns, Glaukos chairman and chief executive officer. 'These important milestones will not only help us maintain and grow our presence in Europe but also advance and accelerate our broader Interventional Glaucoma initiatives globally. We are eager to commence commercial launch activities for these novel MIGS therapies over the coming months." These certifications affirm that iStent infinite and iStent inject W meet the stringent requirements of the EU MDR – a new, robust framework established to ensure high standards of quality, safety and effectiveness for medical devices marketed in the EU. Glaukos is proud to be the corporate pioneer and global market leader in MIGS, with its family of iStent technologies supported by nearly 400 peer-reviewed publications, 20 plus years of clinical and commercial experience and more than one million iStent devices implanted worldwide since its inception. The company believes it offers the industry's most comprehensive offering of minimally-invasive, tissue-sparing glaucoma solutions, supporting its goal to provide a full range of options to fit surgeons' individual glaucoma treatment algorithms that offer the most favorable short- and long-term benefit-to-risk calculus at every stage of disease progression, from ocular hypertension through refractory disease, and in both combo-cataract and standalone procedures. About Glaukos Glaukos ( is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012. In 2024, Glaukos commenced commercial launch activities for iDose ® TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical designed to deliver 24/7 glaucoma drug therapy inside the eye for extended periods of time. Glaukos also markets the only FDA-approved corneal cross-linking therapy utilizing a proprietary bio-activated pharmaceutical for the treatment of keratoconus, a rarely diagnosed corneal disorder. Glaukos continues to successfully develop and advance a robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases. About iStent infinite ® Trabecular Micro-Bypass System (U.S.) Indication for Use: The iStent infinite Trabecular Micro-Bypass System Model iS3 is an implantable device intended to reduce the intraocular pressure (IOP) of the eye. It is indicated for use in adult patients with primary open-angle glaucoma in whom previous medical and surgical treatment has failed. Contraindications: The iStent infinite is contraindicated in eyes with angle-closure glaucoma where the angle has not been surgically opened, acute traumatic, malignant, active uveitic, or active neovascular glaucoma, discernible congenital anomalies of the anterior chamber (AC) angle, retrobulbar tumor, thyroid eye disease, or Sturge-Weber Syndrome or any other type of condition that may cause elevated episcleral venous pressure. Warnings: Gonioscopy should be performed prior to surgery to exclude congenital anomalies of the angle, PAS, rubeosis, or conditions that would prohibit adequate visualization that could lead to improper placement of the stent and pose a hazard. MRI Information: The iStent infinite is MR-Conditional, i.e., the device is safe for use in a specified MR environment under specified conditions; please see Directions for Use (DFU) label for details. Precautions: The surgeon should monitor the patient postoperatively for proper maintenance of IOP. Three out of 61 participants (4.9%) in the pivotal clinical trial were phakic. Therefore, there is insufficient evidence to determine whether the clinical performance of the device may be different in those who are phakic versus in those who are pseudophakic. Adverse Events: The most common postoperative adverse events reported in the iStent infinite pivotal trial included IOP increase ≥ 10 mmHg vs. baseline IOP (8.2%), loss of BSCVA ≥ 2 lines (11.5%), ocular surface disease (11.5%), perioperative inflammation (6.6%) and visual field loss ≥ 2.5 dB (6.6%). Caution: Federal law restricts this device to sale by, or on the order of, a physician. Please see DFU for a complete list of contraindications, warnings, precautions, and adverse events. For more information, visit
